

11-29-00

11/28/00
JC535 U.S. PTO

Please type a plus sign (+) inside this box ☐

Attorney Docket P1805R1

PATENT

JCS35 U.S. PTO
09/724341

#41A
11/28/00
Box-5ed

CERTIFICATION UNDER 37 CFR 1.10

EL 599 585 318 US: Express Mail Number November 28, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Diane L. Marschang

Diane L. Marschang

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Avi J. Ashkenazi, San Mateo, CA
Kelly H. Dodge, San Mateo, CA
Iqbal Grewal, Redwood City, CA
Kyung Jin Kim, Cupertino, CA
Scot A. Marsters, San Carlos, CA
Robert M. Pitti, El Cerrito, CA
Minhong Yan, Burlingame, CA

Title: **USES OF AGONISTS AND ANTAGONISTS TO MODULATE ACTIVITY OF TNF-RELATED MOLECULES**

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☒ This is a non-provisional application claiming priority to provisional application no. 60/182,938, filed February 16, 2000 and provisional application no. 60/226,986, filed August 22, 2000 the entire disclosures of which are hereby incorporated by reference.
- ☐ This is a ☐ continuation-in-part ☐ continuation ☐ divisional application claiming priority to application Serial Number __, filed __, the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

105 pages of specification
9 pages of claims

09724341-1 11/28/00

1 page(s) of abstract
29 sheet(s) of drawings
 [] formal [X] informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

X An executed declaration of the inventor(s) [] is enclosed [X] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

— A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

— A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.

(for cont./div.)

— The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

— Cancel in this application original claims _ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

— A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

X Amend the specification by inserting before the first line the sentence:

— This is a

X non-provisional application
 — continuation
 — divisional
 — continuation-in-part

of co-pending application(s)

— Serial No. _ filed on_, which application(s) is(are) incorporated herein by reference and to

AI
Cont.

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

_____ A petition, fee and/or response has been filed to extend the term in the pending prior application until

_____ A copy of the petition for extension of time in the **prior** application is attached.

11. Correspondence Address:

X Address all future communications to:

Genentech, Inc.
Attn: Diane L. Marschang
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-5416

Respectfully submitted,
GENENTECH, INC.

Date: November 28, 2000

By: Diane L. Marschang
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE

003227 "T4E4260